1. Search Result
Search Result
Results for "

Short peptide sequence

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

4

Biochemical Assay Reagents

17

Peptides

1

Click Chemistry

Cat. No. Product Name Target Research Area
  • HY-P2193

    Peptides Infection
    TAT-amide is a cell penetrating peptide. Cell-penetrating peptides (CPPs) are short amino acid sequences able to enter different cells .
  • HY-P2665

    Peptides Others
    Lymphocyte activating pentapeptide is a short peptide sequence found in the Fc region of human IgG1 that has the ability to activate lymphocytes. Lymphocyte activating pentapeptide can be used to study the activation mechanisms of B cells and T cells, and their role in immune responses .
  • HY-P1965

    Peptides Cancer
    Ac-IEVDIDV TFA is a short peptide sequence with Ac at the end.
  • HY-P1963

    Peptides Cancer
    Ac-IEVDIDVEH TFA is a short peptide sequence with Ac at the end.
  • HY-P1964

    Peptides Cancer
    Ac-IEVDIDVE TFA is a short peptide sequence with Ac at the end.
  • HY-P1966

    Peptides Cancer
    Ac-IEVDID TFA is a short peptide sequence with Ac at the end.
  • HY-P1967

    Peptides Cancer
    Ac-VDID TFA is a short peptide sequence with Ac at the end.
  • HY-P3526

    Biochemical Assay Reagents Others
    YQEAFRRFFGPV is a short peptide sequence containing 12 amino acid residues with some emulsification ability
  • HY-P2193A

    Peptides Infection
    TAT-amide TFA is a cell penetrating peptide. Cell-penetrating peptides (CPPs) are short amino acid sequences able to enter different cells .
  • HY-P1734

    PKC Neurological Disease
    Ac-MBP 1-11, a short peptide sequence, is the major encephalitogenic epitope in myelin basic protein (MBP) .
  • HY-P10709

    Biochemical Assay Reagents Cardiovascular Disease Cancer
    CREKA peptide is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity .
  • HY-P10709A

    Biochemical Assay Reagents Cardiovascular Disease Cancer
    CREKA peptide acetate is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. CREKA peptide acetate can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity .
  • HY-P10739

    MMP Inflammation/Immunology
    WYRGRL, a collagen II-targeting peptide, can bind to collagen II α1. WYRGRL is a short cartilage-targeting peptide sequence. WYRGRL leads to about 72-fold increase of cartilage-targeting efficiency for the peptide-functionalized nanoplatform in vivo .
  • HY-P10705

    Biochemical Assay Reagents Cancer
    KGFRWR is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. KGFRWR can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity .
  • HY-P10496

    Peptides Cancer
    MAGE-A1-derived peptide is a short peptide sequence derived from MAGE-A1 protein. As a tumor-specific antigen, MAGE-A1-derived peptide can be recognized and activated by cytotoxic T lymphocytes (CTLs), thereby generating an immune response to tumor cells expressing MAGE-A1. This immune response can lead to the lysis and death of tumor cells. MAGE-A1-derived peptide can be used in the study of tumor immunity .
  • HY-P10496A

    Peptides Cancer
    MAGE-A1-derived peptide acetate is a short peptide sequence derived from MAGE-A1 protein. As a tumor-specific antigen, MAGE-A1-derived peptide acetate can be recognized and activated by cytotoxic T lymphocytes (CTLs), thereby generating an immune response to tumor cells expressing MAGE-A1. This immune response can lead to the lysis and death of tumor cells. MAGE-A1-derived peptide acetate can be used in the study of tumor immunity .
  • HY-P10251

    HIV Infection
    HIV gp120 (318-327) is a short sequence of the HIV-1 strain IIIB envelope peptide (rgpgrafvti) that corresponds to the conserved C-terminal region of the glycoprotein. HIV gp120 (318-327) is part of the HIV vaccine V3 peptide epitope, also known as the I10 peptide. However, HIV gp120 (318-327) lacks the A2 anchor residues recognized by epitope-specific CTLs but has structural features that confer promiscuous A2 binding .

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: